Answers are grounded in this paper and cite their sources.
In clinical trials, itch and sleep disturbances associated with atopic dermatitis (AD) are typically assessed using subjective patient-reported outcomes (PROs). This study explored the clinical validity of algorithms that derive digital scratch and sleep outcomes from actigraphy data in patients with AD. Algorithms that had previously shown good agreement with video annotation/polysomnography (“gold standard”) data were applied to actigraphy data from 664 adults with moderate-to-severe AD in two phase III monotherapy studies of baricitinib (BREEZE-AD1 and -AD2). The algorithm-determined percentage of the “total sleep opportunity” (period spent sleeping/attempting to sleep) spent asleep was moderately correlated with nocturnal scratch (r=-0.45), with scratch explaining »25% of sleep variation. Patients in the lowest quartile for mean hourly nocturnal scratch duration spent 23% more of their total sleep opportunity asleep, and 107 fewer minutes/night awake after initially falling asleep, than those in the highest quartile. Digital outcomes and PROs for itch/scratch and sleep disturbance were weakly correlated (r<0.30). Both PROs and digital endpoints significantly improved with baricitinib 4 mg whereas placebo treatment led to improvements in PROs but no improvement of digital outcomes. Findings from this evolving technology indicate that objective digital endpoints can provide clinically relevant insights that complement PROs.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: